Enzyme kinetics and binding studies on inhibitors of MEK protein kinase

Biochemistry

Volumn 47, Issue 17, 2008, Pages 5017-5027

  VanScyoc, Wendy S ^a,b   Holdgate, Geoffrey A ^a   Sullivan, Jane E ^a   Ward, Walter H J ^a  

^a ASTRAZENECA   (United Kingdom)

^b GE HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINETRIPHOSPHATE; BINDING ENERGY; BUTADIENE; CONCENTRATION (PROCESS); ENZYME KINETICS; PHOSPHORYLATION; PROTEINS; REACTION KINETICS;

BINDING AFFINITY; INHIBITION OF CATALYSIS (IOC); INHIBITORS; PREVENTION OF ACTIVATION (POA); PROTEIN KINASE;

ENZYME INHIBITION;

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ADENOSINE TRIPHOSPHATE; ALKYL GROUP; AMIDE; ANTHRANILIC ACID; B RAF KINASE; METHAQUALONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; QUINOLINE DERIVATIVE; 1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2-(2-CHLORO-4-IODOPHENYLAMINO)-N-CYCLOPROPYLMETHOXY-3,4-DIFLUOROBENZAMIDE; BENZAMIDE DERIVATIVE; ENZYME INHIBITOR; NITRILE; QUINOLINE;

ARTICLE; BINDING AFFINITY; CONCENTRATION (PARAMETERS); ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; IC 50; PRIORITY JOURNAL; CATALYSIS; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; KINETICS; METABOLISM; PROTEIN BINDING; THERMODYNAMICS;

POA;

ADENOSINE TRIPHOSPHATE; BENZAMIDES; BUTADIENES; CATALYSIS; ENZYME ACTIVATION; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; KINETICS; MAP KINASE KINASE 1; NITRILES; PROTEIN BINDING; QUINOLINES; THERMODYNAMICS;

EID: 42449089351     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi701811x     Document Type: Article

References (38)

1. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934.
2. Cohen, P. (2002) Protein kinases - the major drug targets of the 21st century? Nat. Rev. Drug Discov. 1, 309-315.
3. Cherry, M., and Williams, D. H. (2004) Recent kinase and kinase inhibitor X-ray structures: Mechanisms of inhibition and selectivity insights. Curr. Med. Chem. 11, 663-673.
4. Noble, M. E. M., Endicott, J. A., and Johnson, L. N. (2004) Protein kinase inhibitors: insights into design from structure. Science 303, 1800-1805.
5. Knight, Z. A., and Shokat, K. M. (2005) Features of selective kinase inhibitors. Chem. Biol. 12, 621-637.
6. Sebolt-Leopold, J. E., and Herrera, R. (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937-947.
7. Wallace, E. M., Lyssikatos, J. P., Yeh, T., Winkler, J. D., and Koch, K. (2005) Progress towards theraeutic small molecule MEK inhibitors for use in cancer therapy. Curr. Top. Med. Chem. 5, 215-229.
8. Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., Copeland, R. A., Magolda, R. L., Scherle, P. A., and Trzaskos, J. M. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623-18632.
9. Ahn, N. G., Nahreini, T. S., Tolwinski, N. S., and Resing, K. A. (2001) Pharmacologic inhibitors of MKK1 and MKK2. Methods Enzymol. 332, 417-431.
10. Mansour, S. J., Candia, J. M., Matsuura, J. E., Manning, M. C., and Ahn, N. G. (1996) Interdependent domains controlling the enzymatic activity of mitogen-activated protein kinase kinase 1. Biochemistry 35, 15529-15536.
11. Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Van Becelaere, K., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., Leopold, W. R., and Saltiel, A. R. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5, 810-816.
12. Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., Mueller, W. T., Delaney, A., Omer, C., Sebolt-Leopold, J., Dudley, D. T., Leung, I. K., Flamme, C., Warmus, J., Kaufman, M., Barrett, S., Tecle, H., and Hasemann, C. A. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel non-competitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192-1197.
13. Barrett, S. D., Bridges, A. J., Doherty, A. M., Dudley, D. T., Saltiel, A. R., and Tecle, H. (1999) Preparation of 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives as MEK inhibitors, International Patent, WO 99/01426.
14. Boyle, F. T., Gibson, K. H., Poyser, J. P., and Turner, P. (2000) Preparation of quinoline derivatives as inhibitors of MEK enzymes, International Patent, WO 00/068201.
15. Boyle, F. T., Gibson, K. H., and Foote, K. M. (2002) Substituted quinolines as antitumour agents, International Patent, WO 02/044166.
16. Crawley, G. C., McKerrecher, D., Poyser, J. P., Hennequin, L. F., Plé, P., and Lambert, C. M.-P. (2001) Quinazoline derivatives, International Patent, WO 01/04102.
17. Sullivan, J. E., Holdgate, G. A., Campbell, D., Timms, D., Gerhardt, S., Breed, J., Breeze, A. L., Bermingham, A., Pauptit, R. A., Norman, R. A., Embrey, K. J., Read, J., VanScyoc, W. S., and Ward, W. H. J. (2005) Prevention of MKK6-dependent activation by binding to p38α MAP kinase. Biochemistry 44, 16475-16490.
18. Mannervik, B. (1982) Regression analysis, experimental error, and statistical criteria in the design and analysis of experiments for discrimination between rival kinetic models. Methods Enzymol. 87, 370-390.
19. Segel, I. H. (1975) Enzyme Kinetics, pp 203-206, John Wiley & Sons, New York.
20. 50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108.
21. Prowse, C. N., Hagopian, J. C., Cobb, M. H., Ahn, N. G., and Lew, J. (2000) Catalytic reaction pathway for the mitogen-activated protein kinase ERK2. Biochemistry 39, 6258-6266.
22. Smith, C. K., and Windsor, W. T. (2007) Thermodynamics of nucleotide and non-ATP-competitive inhibitor binding to MEK1 by circular dichroism and isothermal titration calorimetry. Biochemistry 46, 1358-1367.
23. Feng, B. Y., Shelat, A., Doman, T. N., Guy, R. K., and Shoichet, B. K. (2005) High-throughput assays for promiscuous inhibitors. Nat. Chem. Biol. 1, 146-148.
24. Davies, S. P., Reddy, H., Caiavano, M., and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105.
25. Duncia, J. V., Santella, J. B., III, Higley, C. A., Pitts, W. J., Wityak, J., Frietze, W. E., Rankin, F. W., Sun, J. H., Earl, R. A., Tabaka, A. C., Teleha, C. A., Blom, K. F., Favata, M. F., Manos, E. J., Daulerio, A. J., Stradley, D. A., Horiuchi, K., Copeland, R. A., Schede, P. A., Trzaskos, J. M., Magolda, R. L., Trainor, G. L., Wexler, R. R., Hobbs, F. W., and Olson, R. E. (1998) MEK inhibitors: the chemistry and biological activity of U-0126, its analogs, and cyclization products. Bioorg. Med. Chem. Lett. 8, 2839-2844.
26. Horiuchi, K. Y., Scherle, P. A., Trzaskos, J. M., and Copeland, R. A. (1998) Competitive inhibition of MAP kinase activation by a peptide representing the alpha C helix of ERK. Biochemistry 37, 8879-8885.
27. Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bondman, W., Clarkson, B., Superti-Furga, G., and Kuriyan, J. (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859-871.
28. Atwell, S., Adams, J. M., Badger, J., Buchanan, M. D., Feil, I. K., Froning, K. J., Gao, X., Hendle, J., Keegan, K., Leon, B. C., Muller-Dieckmann, H. J., Nienaber, V. L., Noland, B. W., Post, K., Rajashankar, K. R., Ramos, A., Russell, M., Burley, S. K., and Buchanan, S. G. (2004) A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem. 279, 55827-55832.
29. Davidson, W., Frego, L., Peet, G. W., Kroe, R. R., Labadia, M. E., Lukas, S. M., Snow, R. J., Jakes, S., Grygon, C. A., Pargellis, C., and Werneburg, B. G. (2004) Discovery and characterization of a substrate selective p38α inhibitor. Biochemistry 43, 11658-11671.
30. Duntiz, J. D. (1995) Win some, lose some: enthalpy-entropy compensation in weak intermolecular interactions. Chem. Biol. 2, 709-712.
31. Engh, R. A., Girod, A., Kinzel, V., Huber, R., and Bossemeyer, D. (1996) Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity. J. Biol. Chem. 271, 26157-26164.
32. Collins, I., Caldwell, J., Fonseca, T., Donald, A., Bavetsias, V., Hunter, L.-J. K., Garrett, M. D., Rowlands, M. G., Aherne, G. W., Davies, T. G., Berdini, V., Woodhead, S. J., Davis, D., Seavers, L. C. A., Wyatt, P. G., Workman, P., and McDonald, E. (2006) Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Bioorg. Med. Chem. 14, 1255-1273.
33. Hartshorn, M. J., Murray, C. W., Cleasby, A., Frederickson, M., Tickle, I. J., and Jhoti, H. (2005) Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 48, 403-413.
34. Hajduk, P. J., Bures, M., Praestgaard, J., and Fesik, S. W. (2000) Privileged molecules for protein binding identified from NMR-based screening. J. Med. Chem. 43, 3443-3447.
35. Lo, M.-C., Aulabaugh, A., Jin, G., Cowling, R., Bard, J., Malamas, M., and Ellestad, G. (2004) Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 332, 153-159.
36. Muckenschnabel, I., Falchetto, R., Mayr, L. M., and Filipuzzi, I. (2004) SpeedScreen: label-free liquid chromatography-mass spectrometry-based high-throughput screening for the discovery of orphan protein ligands. Anal. Biochem. 324, 241-249.
37. Fabian, M. A., III, Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., Ford, J. M., Galvin, M., Gerlach, J. L., Grotzfeld, R. M., Herrgard, S., Insko, D. E., Insko, M. A., Lai, A. G., Lelias, J. M., Mehta, S. A., Milanov, Z. V., Velasco, A. M., Wodicka, L. M., Patel, H. K., Zarrinkar, P. P., and Lockhart, D. J. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336.
38. Swinney, D. C. (2006) Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. Curr. Top. Med. Chem. 6, 461-478.